Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Anna Melissa Schlitter

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6431-2036; OpenAlex author ID A5056045552. Sources: OpenAlex.

Their work

Papers
23
Trials
0
Grants
0
Labs led
0
Collaborators
118
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: 2 papers · 2018: 4 papers · 2019: none · 2020: 1 paper · 2021: 3 papers · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 23

  1. Modeling pancreatic cancer tumor stroma co-evolution in an in ovo model Co-author DOI 10.64898/2026.06.26.734719↗
  2. Neural invasion severity is a strong predictor of local recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.surg.2024.109018↗
  3. Expression of the membrane tetraspanin claudin 18 on cancer cells promotes T lymphocyte infiltration and antitumor immunity in pancreatic cancer. Co-author DOI 10.1016/j.immuni.2024.04.021↗
  4. GATA4 and GATA6 loss-of-expression is associated with extinction of the classical programme and poor outcome in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325803↗
  5. Molecular heterogeneity and commonalities in pancreatic cancer precursors with gastric and intestinal phenotype. Co-author DOI 10.1136/gutjnl-2021-326550↗
  6. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. Co-author DOI 10.15252/emmm.202114876↗
  7. MALDI-MSI: A Powerful Approach to Understand Primary Pancreatic Ductal Adenocarcinoma and Metastases. Co-author DOI 10.3390/molecules27154811↗
  8. Bcl3 Couples Cancer Stem Cell Enrichment With Pancreatic Cancer Molecular Subtypes. Co-author DOI 10.1053/j.gastro.2021.03.051↗
  9. Native glycan fragments detected by MALDI mass spectrometry imaging are independent prognostic factors in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s13550-021-00862-y↗
  10. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma. Co-author DOI 10.14670/hh-18-332↗
  11. Multiparametric Modelling of Survival in Pancreatic Ductal Adenocarcinoma Using Clinical, Histomorphological, Genetic and Image-Derived Parameters. Co-author DOI 10.3390/jcm9051250↗
  12. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Co-author DOI 10.1016/j.devcel.2018.05.025↗
  13. Stromal heterogeneity in pancreatic cancer and chronic pancreatitis. Co-author DOI 10.1016/j.pan.2018.05.004↗
  14. R0 Versus R1 Resection Matters after Pancreaticoduodenectomy, and Less after Distal or Total Pancreatectomy for Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002345↗
  15. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response. Co-author DOI 10.1158/1078-0432.ccr-17-2180↗
  16. pT but not pN stage of the 8th TNM classification significantly improves prognostication in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejca.2017.06.034↗
  17. Extended RAS analysis and correlation with overall survival in advanced pancreatic cancer. Co-author DOI 10.1038/bjc.2017.115↗
  18. Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0358-5↗
  19. Erratum to: Next-generation sequencing reveals novel differentially regulated mRNAs, lncRNAs, miRNAs, sdRNAs and a piRNA in pancreatic cancer. Co-author DOI 10.1186/s12943-015-0401-6↗
  20. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience. Co-author DOI 10.1245/s10434-015-4851-2↗
  21. pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104. Co-author DOI 10.1186/1471-2407-14-624↗
  22. [New insights into the origin of pancreatic cancer. Role of atypical flat lesions in pancreatic carcinogenesis]. Co-author DOI 10.1007/s00292-012-1673-x↗
  23. How fibrosis influences imaging and surgical decisions in pancreatic cancer. Co-author DOI 10.3389/fphys.2012.00389↗

Closest collaborators

The 25 strongest of 118 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wilko Weichert · 9 shared papers, 2017–2023 · strength 0.89
  2. Iréne Esposito · 10 shared papers, 2012–2023 · strength 0.80
  3. İhsan Ekin Demir · 6 shared papers, 2017–2025 · strength 0.70
  4. Helmut Friess · 5 shared papers, 2017–2025 · strength 0.61
  5. Rickmer Braren · 5 shared papers, 2015–2025 · strength 0.58
  6. Guralp Onur Ceyhan · 5 shared papers, 2017–2025 · strength 0.52
  7. Roland Michael Schmid · 4 shared papers, 2020–2026 · strength 0.51
  8. Jens Thomas Siveke · 5 shared papers, 2014–2023 · strength 0.40
  9. Maximilian Reichert · 3 shared papers, 2018–2026 · strength 0.39
  10. Günter Schneider · 3 shared papers, 2018–2026 · strength 0.39
  11. Dieter Saur · 3 shared papers, 2018–2026 · strength 0.39
  12. Lena Häberle · 3 shared papers, 2018–2023 · strength 0.37
  13. Georgios A. Kaissis · 2 shared papers, 2020–2025 · strength 0.33
  14. H. Carlo Maurer · 2 shared papers, 2022–2026 · strength 0.33
  15. Roland Rad · 2 shared papers, 2022–2026 · strength 0.33
  16. Alexander Muckenhuber · 4 shared papers, 2017–2021 · strength 0.31
  17. Stephan Schorn · 2 shared papers, 2018–2025 · strength 0.31
  18. Günter Klöppel · 3 shared papers, 2012–2023 · strength 0.26
  19. Helmut Frieß · 4 shared papers, 2012–2020 · strength 0.24
  20. Wolfram Trudo Knoefel · 2 shared papers, 2018–2023 · strength 0.24
  21. Matthias M. Gaida · 1 shared paper, 2025 · strength 0.24
  22. Bo Kong · 4 shared papers, 2015–2022 · strength 0.23
  23. Sladjana Zagorac · 2 shared papers, 2021–2023 · strength 0.22
  24. Stefanie Bärthel · 1 shared paper, 2026 · strength 0.22
  25. Daniele Lucarelli · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.